This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.
Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available.
Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).
Measurable disease per RECIST 1.1
ECOG performance status ≤ 2
Inability to provide informed consent
Inability to obtain a (new) biopsy for molecular profiling
Pregnancy or breastfeeding.
Other active malignancies requiring therapy.
Single group
Personalised treatment
Combination productThe therapy will consist of (one or more) approved drugs.
Feasibility
Number and proportion of enrolled patients who initiate study treatment.
Safety
Number and proportion of patients who experience treatment-related adverse events (CTCAE v5.0).
Preliminary efficacy
Disease control rate (DCR) at 3 months, defined as the number and proportion of patients achieving stable disease (SD), partial response (PR), or complete response (CR), according to RECIST 1.1.
Click on the lead sponsor to view all of their trials.
Radboud University Medical Center
Lead sponsor
Maastricht University
Collaborator
EU Horizon
Collaborator
Horizon Europe
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
